Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of the central nervous system

被引:0
作者
Wang, Yali [1 ]
Han, Jiefei [1 ]
Yin, Shuo [1 ]
Yang, Shoubo [1 ]
Kang, Xun [1 ]
Zheng, Xiaohong [1 ]
Duan, Ling [1 ]
Li, Shenglan [1 ]
Jiang, Bo [1 ]
Li, Wenbin [1 ]
Chen, Feng [1 ]
机构
[1] Beijing Tiantan Hosp, Canc Ctr, Dept Neurooncol, Beijing 100070, Peoples R China
基金
国家重点研发计划;
关键词
zanubrutinib; primary central nervous system lymphoma; diffuse large B-cell lymphoma; relapsed/refractory; tumor mutation burden; PRIMARY CNS LYMPHOMA; CAR T-CELL; IBRUTINIB MONOTHERAPY; THERAPY; BTK; MANAGEMENT; BLOCKADE; EFFICACY;
D O I
10.1080/10428194.2025.2451066
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL) usually have a poor prognosis and limited treatment options. We respectively reviewed 38 patients with R/R PCNSL treated with zanubrutinib-based regimens in our center. The overall response rate, complete response rate and disease control rate were 76.3%, 47.4% and 92.1%, respectively. The median progression-free survival (PFS) was 31.0 months, the median overall survival (OS) was not reached. Unitivariate analysis by Cox's proportional hazards model revealed that overall response (vs. no response, HR = 0.18, 95%CI:0.07,0.48, p = 0.001), long duration of zanubrutinib (>= 6months vs 2-5 months, HR = 0.20, 95%CI:0.06,0.63, p = 0.006) were independent factors for prolonged PFS. The log-rank analysis indicated a prolongation of PFS among patients exhibiting a higher Tumor mutational burden (TMB, >= 14.75muts/Mb) following zanubrutinib-based treatment (p = 0.016). Our data showed promising efficacy with tolerable safety of zanubrutinib-based therapies in patients with R/R PCNSL. Long duration of zanubrutinib may be associated with prolonged PFS.
引用
收藏
页码:869 / 878
页数:10
相关论文
共 50 条
[1]   Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].
Abrey, LE ;
Batchelor, TT ;
Ferreri, AJM ;
Gospodarowicz, M ;
Pulczynski, EJ ;
Zucca, E ;
Smith, JR ;
Korfel, A ;
Soussain, C ;
DeAngelis, LM ;
Neuwelt, EA ;
O'Neill, BP ;
Thiel, E ;
Shenkier, T ;
Graus, F ;
van den Bent, M ;
Seymour, JF ;
Poortmans, P ;
Armitage, JO ;
Cavalli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043
[2]   Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial [J].
Al-Sawaf, Othman ;
Ligtvoet, Rudy ;
Robrecht, Sandra ;
Stumpf, Janina ;
Fink, Anna-Maria ;
Tausch, Eugen ;
Schneider, Christof ;
Boettcher, Sebastian ;
Mikusko, Martin ;
Ritgen, Matthias ;
Schetelig, Johannes ;
von Tresckow, Julia ;
Vehling-Kaiser, Ursula ;
Gaska, Tobias ;
Wendtner, Clemens Martin ;
Chapuy, Bjoern ;
Fischer, Kirsten ;
Kreuzer, Karl-Anton ;
Stilgenbauer, Stephan ;
Staber, Philipp ;
Niemann, Carsten ;
Hallek, Michael ;
Eichhorst, Barbara .
NATURE MEDICINE, 2024, 30 (01) :240-+
[3]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[4]   Does BTKi improve CAR T-cell in MCL? [J].
Boardman, Alexander P. ;
Palomba, M. Lia .
BLOOD, 2024, 143 (08) :653-655
[5]   Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia [J].
Brown, Jennifer R. ;
Harb, Wael A. ;
Hill, Brian T. ;
Gabrilove, Janice ;
Sharman, Jeff P. ;
Schreeder, Marshall T. ;
Barr, Paul M. ;
Foran, James M. ;
Miller, Thomas P. ;
Burger, Jan A. ;
Kelly, Kevin R. ;
Mahadevan, Daruka ;
Ma, Shuo ;
Li, Yan ;
Pierce, Daniel W. ;
Barnett, Evelyn ;
Marine, Jeffrey ;
Miranda, Monika ;
Azaryan, Ada ;
Yu, Xujie ;
Nava-Parada, Pilar ;
Mei, Jay ;
Kipps, Thomas J. .
HAEMATOLOGICA, 2016, 101 (07) :295-298
[6]   Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Harrington, Bonnie ;
O'Brien, Susan ;
Jones, Jeffrey A. ;
Schuh, Anna ;
Devereux, Steve ;
Chaves, Jorge ;
Wierda, William G. ;
Awan, Farrukh T. ;
Brown, Jennifer R. ;
Hillmen, Peter ;
Stephens, Deborah M. ;
Ghia, Paolo ;
Barrientos, Jacqueline C. ;
Pagel, John M. ;
Woyach, Jennifer ;
Johnson, Dave ;
Huang, Jane ;
Wang, Xiaolin ;
Kaptein, Allard ;
Lannutti, Brian J. ;
Covey, Todd ;
Fardis, Maria ;
McGreivy, Jesse ;
Hamdy, Ahmed ;
Rothbaum, Wayne ;
Izumi, Raquel ;
Diacovo, Thomas G. ;
Johnson, Amy J. ;
Furman, Richard R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332
[7]   The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System [J].
Cao, Tingyu ;
Wang, Zengguang ;
Zhu, Xiaodong .
JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 :6427-6438
[8]   IBRUTINIB MONOTHERAPY IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE CASE SERIES [J].
Chamoun, Kamal ;
Choquet, Sylvain ;
Boyle, Eileen ;
Houillier, Caroline ;
Larrieu-Ciron, Delphine ;
Al Jijakli, Ahmad ;
Delrieu, Vanessa ;
Delwail, Vincent ;
Morschhauser, Franck ;
Hoang-Xuan, Khe ;
Soussain, Carole .
NEUROLOGY, 2017, 88 (01) :101-102
[9]   Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients [J].
Cook, Michael R. ;
Dorris, C. Scott ;
Makambi, Kepher H. ;
Luo, Yutong ;
Munshi, Pashna N. ;
Donato, Michelle ;
Rowley, Scott ;
Saad, Ayman ;
Goy, Andre ;
Dunleavy, Kieron ;
Ali, Alaa .
BLOOD ADVANCES, 2023, 7 (01) :32-39
[10]   B cell antigen receptor signaling 101 [J].
Dal Porto, JM ;
Gauld, SB ;
Merrell, KT ;
Mills, D ;
Pugh-Bernard, AE ;
Cambier, J .
MOLECULAR IMMUNOLOGY, 2004, 41 (6-7) :599-613